Epiome AI secures £510k seed funding for neurodegenerative disease biomarker platform

Inferring epigenetic markers of neurodegenerative diseases from blood samples is the core focus of Epiome Ai Ltd, which recently closed a £510.9k seed funding round. The London-based biotechnology company provides an AI-driven biomarker discovery platform designed for pharmaceutical companies, researchers, and diagnostic developers.

Incorporated in 2024, the business operates in the field of research and experimental development. The firm employed two people during the financial year that ended 31 July 2025. This latest capital injection was formalised in June 2026 (with both the allotment and filing dates occurring during that month).